VOCs in Patients With Acute Cardiogenic Chest Pain

Acute Coronary Syndrome Clinical Trial

Official title:

Application of Emergency Rapid Detection of Expiratory Volatile Organic Compounds (VOCs) in Patients With Acute Cardiogenic Chest Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06277895
• Other study ID #: KYLL-202401-047
• Status: Recruiting
• Phase: N/A
• Start date: January 26, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Qilu Hospital of Shandong University
• Contact: Yuan Bian, Dr.
• Phone: +8618560083065
• Email: bianyuan[@]sdu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer：Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain

1. VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought.

2. The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1400
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Observation group inclusion criteria:

1. Over 18 years old, male or female;

2. Patients with acute cardiogenic chest pain (see diagnostic criteria);

3. Patient's informed consent.

Inclusion criteria of healthy control group:

1. Over 18 years old, male or female;

2. Centerless cerebrovascular disease, lung disease, no abnormal liver and kidney function, no acute infection recently;

3. Informed consent.

Exclusion Criteria:

1. The patient had difficulty in collecting breath;

2. Patients with terminal illness or receiving palliative care;

3. Have participated in other clinical studies or consider it inappropriate to participate in this study.

Related Conditions & MeSH terms

• Acute Aortic Syndrome
• Acute Coronary Syndrome
• Chest Pain
• Syndrome

Intervention

Diagnostic Test:
• VOCs
test the end-expiratory gas

Locations

Country	Name	City	State
China	Qilu hospital	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Baseline VOCs (aldehydes) levels in healthy population	Baseline VOCs (aldehydes) levels in healthy population	Baseline
Secondary	MACE in patients with cardiogenic chest pain	the relationship between the different VOCs levels and 30-day MACE in patients with cardiogenic chest pain	From enrollment to the end of treatment at 30 days